Skip to main content

editorial

. 1995 Jun 24;310(6995):1621–1622. doi: 10.1136/bmj.310.6995.1621

Chemoprophylaxis in tuberculosis and HIV infection.

J Walley, J Porter

PMCID: PMC2550007 PMID: 7795439

1621

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Edwards D., Kirkpatrick C. H. The immunology of mycobacterial diseases. Am Rev Respir Dis. 1986 Nov;134(5):1062–1071. doi: 10.1164/arrd.1986.134.5.1062. [DOI] [PubMed] [Google Scholar]
Goodgame R. W. AIDS in Uganda--clinical and social features. N Engl J Med. 1990 Aug 9;323(6):383–389. doi: 10.1056/NEJM199008093230605. [DOI] [PubMed] [Google Scholar]
Pape J. W., Jean S. S., Ho J. L., Hafner A., Johnson W. D., Jr Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993 Jul 31;342(8866):268–272. doi: 10.1016/0140-6736(93)91817-6. [DOI] [PubMed] [Google Scholar]
Schopper D., Walley J. Care for AIDS patients in developing countries: a review. AIDS Care. 1992;4(1):89–102. doi: 10.1080/09540129208251623. [DOI] [PubMed] [Google Scholar]
Selwyn P. A., Hartel D., Lewis V. A., Schoenbaum E. E., Vermund S. H., Klein R. S., Walker A. T., Friedland G. H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545–550. doi: 10.1056/NEJM198903023200901. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES